Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Psilocybin and MDMA for Post-traumatic Stress Disorder (PTSD)
NCT06989957Phase 1Recruiting
- Sponsor
- Johns Hopkins University
- Start
- Sep 2025
- Primary completion
- Aug 2028
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of psilocybin and midomafetamine in post-traumatic stress disorder (PTSD) (2 arms), sponsored by Johns Hopkins University. Primary endpoints: Incidence of Adverse Events at 30 weeks, Columbia Suicide Severity Rating Scale at 33 weeks and 3 more. Started Sep 2025; status: recruiting.
02
Drugs
psilocybinmidomafetamine
03
Conditions
post-traumatic stress disorder (PTSD)
Beyond the preview
Go deeper on NCT06989957.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06989957.